• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国国立卫生研究院造血细胞移植迟发效应倡议:研究方法与研究设计工作组报告

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.

作者信息

Shaw Bronwen E, Hahn Theresa, Martin Paul J, Mitchell Sandra A, Petersdorf Effie W, Armstrong Gregory T, Shelburne Nonniekaye, Storer Barry E, Bhatia Smita

机构信息

Department of Medicine, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

出版信息

Biol Blood Marrow Transplant. 2017 Jan;23(1):10-23. doi: 10.1016/j.bbmt.2016.08.018. Epub 2016 Aug 30.

DOI:10.1016/j.bbmt.2016.08.018
PMID:27590102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5182148/
Abstract

The increasing numbers of hematopoietic cell transplantations (HCTs) performed each year, the changing demographics of HCT recipients, the introduction of new transplantation strategies, incremental improvement in survival, and the growing population of HCT survivors demand a comprehensive approach to examining the health and well-being of patients throughout life after HCT. This report summarizes strategies for the conduct of research on late effects after transplantation, including consideration of the study design and analytic approaches; methodologic challenges in handling complex phenotype data; an appreciation of the changing trends in the practice of transplantation; and the availability of biospecimens to support laboratory-based research. It is hoped that these concepts will promote continued research and facilitate the development of new approaches to address fundamental questions in transplantation outcomes.

摘要

每年进行的造血细胞移植(HCT)数量不断增加,HCT受者的人口统计学特征不断变化,新移植策略的引入,生存率的逐步提高,以及HCT幸存者群体的不断扩大,都需要一种全面的方法来检查HCT后患者一生的健康和福祉。本报告总结了移植后迟发效应的研究策略,包括对研究设计和分析方法的考虑;处理复杂表型数据的方法学挑战;对移植实践变化趋势的认识;以及支持基于实验室研究的生物标本的可用性。希望这些概念将促进持续的研究,并有助于开发新方法来解决移植结果中的基本问题。

相似文献

1
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.美国国立卫生研究院造血细胞移植迟发效应倡议:研究方法与研究设计工作组报告
Biol Blood Marrow Transplant. 2017 Jan;23(1):10-23. doi: 10.1016/j.bbmt.2016.08.018. Epub 2016 Aug 30.
2
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.美国国立卫生研究院造血细胞移植迟发效应倡议:制定改善生存及长期预后的建议。
Biol Blood Marrow Transplant. 2017 Jan;23(1):6-9. doi: 10.1016/j.bbmt.2016.10.020. Epub 2016 Oct 29.
3
National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report.美国国立卫生研究院血液与骨髓移植迟发效应倡议:医疗服务提供工作组报告
Biol Blood Marrow Transplant. 2017 May;23(5):717-725. doi: 10.1016/j.bbmt.2016.09.025. Epub 2016 Oct 3.
4
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.美国国立卫生研究院造血细胞移植迟发效应倡议:以患者为中心的结局工作组报告。
Biol Blood Marrow Transplant. 2017 Apr;23(4):538-551. doi: 10.1016/j.bbmt.2016.09.011. Epub 2016 Sep 19.
5
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.美国国立卫生研究院造血细胞移植迟发效应倡议:后续肿瘤工作组报告。
Biol Blood Marrow Transplant. 2017 Mar;23(3):367-378. doi: 10.1016/j.bbmt.2016.09.005. Epub 2016 Sep 12.
6
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.美国国立卫生研究院造血细胞移植后期效应计划:免疫失调与病理生物学工作组报告
Biol Blood Marrow Transplant. 2017 Jun;23(6):870-881. doi: 10.1016/j.bbmt.2016.10.001. Epub 2016 Oct 14.
7
Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary.儿童造血细胞移植的肺部并发症。美国国立卫生研究院研讨会总结。
Ann Am Thorac Soc. 2021 Mar;18(3):381-394. doi: 10.1513/AnnalsATS.202001-006OT.
8
Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.镰状细胞病和地中海贫血患儿造血干细胞移植后期效应的当前结果及未来研究重点:第二届儿科血液和骨髓移植联盟国际儿科造血干细胞移植后期效应会议的共识声明
Biol Blood Marrow Transplant. 2017 Apr;23(4):552-561. doi: 10.1016/j.bbmt.2017.01.009. Epub 2017 Jan 5.
9
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.美国国立卫生研究院造血细胞移植迟发效应倡议:心血管疾病及相关危险因素工作组报告。
Biol Blood Marrow Transplant. 2017 Feb;23(2):201-210. doi: 10.1016/j.bbmt.2016.08.019. Epub 2016 Aug 30.
10
Surviving the cure: long term followup of hematopoietic cell transplant recipients.治愈后的生存:造血细胞移植受者的长期随访。
Bone Marrow Transplant. 2013 Sep;48(9):1145-51. doi: 10.1038/bmt.2012.258. Epub 2013 Jan 7.

引用本文的文献

1
Enhancing biofilm disruption and bactericidal efficiency using vancomycin-loaded microbubbles in sonodynamic therapy.在声动力疗法中使用载万古霉素微泡增强生物膜破坏和杀菌效率。
JAC Antimicrob Resist. 2025 Mar 19;7(2):dlaf045. doi: 10.1093/jacamr/dlaf045. eCollection 2025 Apr.
2
Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry.HCT 后在 CIBMTR 和加利福尼亚癌症登记处的实体瘤累积发病率估计。
Blood Adv. 2024 Aug 13;8(15):4102-4112. doi: 10.1182/bloodadvances.2024012693.
3
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.

本文引用的文献

1
Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.2014年欧洲造血干细胞移植:每年超过4万例移植手术。
Bone Marrow Transplant. 2016 Jun;51(6):786-92. doi: 10.1038/bmt.2016.20. Epub 2016 Feb 22.
2
Haploidentical hematopoietic stem cell transplantation: state of art.单倍体相合造血干细胞移植:现状
Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S1-5. doi: 10.1038/bmt.2015.86.
3
Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.
国际移植和细胞治疗长期幸存者的筛查和预防建议:2023 年更新版。
Bone Marrow Transplant. 2024 Jun;59(6):717-741. doi: 10.1038/s41409-023-02190-2. Epub 2024 Feb 27.
4
International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.国际移植和细胞治疗长期幸存者筛查和预防建议:2023 年更新版。
Transplant Cell Ther. 2024 Apr;30(4):349-385. doi: 10.1016/j.jtct.2023.12.001. Epub 2024 Feb 27.
5
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.异基因移植治疗骨髓增生异常综合征和继发性急性髓系白血病后治疗相关死亡率与竞争死亡原因的比较。
Leukemia. 2019 Mar;33(3):686-695. doi: 10.1038/s41375-018-0302-y. Epub 2018 Dec 20.
6
Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities.基于价值的造血细胞移植和细胞治疗:挑战与机遇。
Curr Hematol Malig Rep. 2018 Apr;13(2):125-134. doi: 10.1007/s11899-018-0444-z.
7
Long-term complications after hematopoietic cell transplantation.造血细胞移植后的长期并发症。
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):220-227. doi: 10.1016/j.hemonc.2017.05.009. Epub 2017 Jun 13.
8
Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.50至64岁接受化疗或化疗加异基因造血细胞移植治疗的急性髓系白血病患者的医疗费用及使用情况。
Biol Blood Marrow Transplant. 2017 Jun;23(6):1021-1028. doi: 10.1016/j.bbmt.2017.02.017. Epub 2017 Mar 2.
9
Late effects of blood and marrow transplantation.血液和骨髓移植的远期效应。
Haematologica. 2017 Apr;102(4):614-625. doi: 10.3324/haematol.2016.150250. Epub 2017 Feb 23.
10
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.美国国立卫生研究院造血细胞移植迟发效应倡议:制定改善生存及长期预后的建议。
Biol Blood Marrow Transplant. 2017 Jan;23(1):6-9. doi: 10.1016/j.bbmt.2016.10.020. Epub 2016 Oct 29.
异基因造血细胞移植受者移植前生活质量的预后意义
Bone Marrow Transplant. 2015 Sep;50(9):1235-40. doi: 10.1038/bmt.2015.122. Epub 2015 Jun 1.
4
Alternative donor transplantation for adults with acute leukemia.成人急性白血病的替代供体移植
Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):272-7. doi: 10.1016/j.beha.2014.10.009. Epub 2014 Oct 15.
5
Concise review: umbilical cord blood transplantation: past, present, and future.简要综述:脐带血移植:过去、现在与未来。
Stem Cells Transl Med. 2014 Dec;3(12):1435-43. doi: 10.5966/sctm.2014-0151. Epub 2014 Nov 5.
6
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.美国注册中心造血干细胞移植供者 HLA 配型概率。
N Engl J Med. 2014 Jul 24;371(4):339-48. doi: 10.1056/NEJMsa1311707.
7
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.造血细胞移植的预处理方案:并非一概而论。
Blood. 2014 Jul 17;124(3):344-53. doi: 10.1182/blood-2014-02-514778. Epub 2014 Jun 9.
8
Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist.21 世纪造血干细胞移植供者来源:当不存在完美匹配时选择理想供者。
Blood. 2014 Jul 17;124(3):334-43. doi: 10.1182/blood-2014-02-514760. Epub 2014 Jun 9.
9
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.自体移植作为多发性骨髓瘤早期治疗的应用和结局趋势。
Biol Blood Marrow Transplant. 2013 Nov;19(11):1615-24. doi: 10.1016/j.bbmt.2013.08.002. Epub 2013 Aug 11.
10
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.在异体造血细胞移植使用率显著增加、受体年龄较大以及使用非亲缘供体的情况下,患者的生存率得到了显著提高。
J Clin Oncol. 2013 Jul 1;31(19):2437-49. doi: 10.1200/JCO.2012.46.6193. Epub 2013 May 28.